01:09 AM EDT, 09/22/2026 (MT Newswires) -- Newron Pharmaceuticals (NWRN.SW) said Tuesday that its net loss for the first half widened, while revenue fell year over year. Net loss for the six months ended June 30 was 16.4 million euros, compared with a net loss of 73,000 euros a year ago. Loss per share moved to 0.798 euro from 0.004 euro. The pharmaceutical company's revenue was 3.2 million euros, compared with 11.9 million euros earlier.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.